close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zura Bio Limited - Class A Ordinary shares (NQ:ZURA)

4.110 UNCHANGED
Delayed Quote Updated: 9:54 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Zura Bio Limited - Class A Ordinary shares

< Previous 1 2 3 4 5 Next >
News headline image
Zura Bio to Participate in the Cantor Global Healthcare Conference
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
From Zura Bio Limited
Via Business Wire
News headline image
Analyst Sees Multi-Billion-Dollar Sales Potential for Zura Bio’s Lead Therapy ↗
William Blair starts Zura Bio (NASDAQ: ZURA) at Outperform, citing tibulizumab's multibillion-dollar potential in autoimmune disease. 
Via Benzinga
ZURA BIO LTD (NASDAQ:ZURA) Q1 2026: Cash Runway Extended Through 2028 as Phase 2 Trials Advance ↗
Via Chartmill
News headline image
Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio to Participate in Upcoming Investor Conferences
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From Zura Bio Limited
Via Business Wire
News headline image
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million ↗
This biotech specializes in monoclonal antibody therapies for inflammatory and immunological diseases with significant unmet needs. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges ↗
RAPT Therapeutics develops oral therapies for oncology and inflammatory diseases, with lead candidates progressing in clinical trials. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst ↗
This clinical-stage biotech develops therapies targeting hematologic disorders, with a pipeline centered on red blood cell biology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Zura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded Warrants
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of Directors
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Appoints Immunology Industry Leader Sandeep Kulkarni, M.D. as Chief Executive Officer
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Reports Business Updates and Outlook for 2026
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Reports Third Quarter 2025 Financial Results and Recent Corporate Updates
From Zura Bio Limited
Via Business Wire
News headline image
Unusual volume stocks are being observed in Wednesday's session. ↗
Discover the stocks with unexpected trading volume in today's session on the US markets. 
Via Chartmill
News headline image
Here are the top movers in Tuesday's session. ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
These stocks are moving in today's session ↗
Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Gainers cbdMD (AMEX:YCBD) shares rose 116.3% to $1.35 during Monday's regular session. The company's market cap stands at $5.5 million. Zura Bio (NASDAQ: ZURA) stock moved upwards by 42.94% to $3.44.... 
Via Benzinga
News headline image
Top stock movements in today's session. ↗
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.